Treatment of symptomatic patients with essential thrombocythemia: effectiveness of anagrelide.
We prospectively evaluated the effect of anagrelide (ANA) on platelets, PF4, F1+2, PAP, PAI-1, and TFPI and erythromelalgia in patients with essential thrombocythemia (ET) receiving anti-aggregants both pre- and post-ANA. At first, we observed a successful reduction of platelets, which was associated with normalization of platelet coagulant and endothelial function and disappearance of erythromelalgia. Secondly, we found a correlation between PF4 and TFPI and between TFPI and thrombosis, suggesting that erythromelalgia may be caused by platelet-mediated endothelial activation. These data may indicate that ANA may be efficacy in the treatment of symptomatic patients with ET.
Cacciola
Rossella R
RR
Institute of Hematology, University of Catania, Italy. rcacciol@unict.it
Cipolla
Antonio
A
Di Francesco
Ernesto
E
Giustolisi
Rosario
R
Cacciola
Emma
E
D000328:Adult; D000368:Aged; D001777:Blood Coagulation / Q000187:drug effects; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000235:genetics; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010976:Platelet Count; D010978:Platelet Factor 4 / Q000235:genetics; D011799:Quinazolines / Q000627:therapeutic use*; D013920:Thrombocythemia, Essential / Q000097:blood / Q000188:drug therapy*; D013927:Thrombosis / Q000097:blood
D008074:Lipoproteins; D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; C051928:lipoprotein-associated coagulation inhibitor; D010978:Platelet Factor 4; C021139:anagrelide